Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totalling 1,770,000 shares, an increase of 9.9% from the June 30th total of 1,610,000 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily trading volume, of 877,600 shares, the days-to-cover ratio is presently 2.0 days.
In other Aptose Biosciences news, VP Jotin Marango sold 20,946 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $6.34, for a total transaction of $132,797.64. Following the transaction, the vice president now owns 179,054 shares of the company’s stock, valued at approximately $1,135,202.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Warren Whitehead sold 18,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $7.11, for a total value of $127,980.00. Following the transaction, the director now directly owns 51,250 shares in the company, valued at approximately $364,387.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 397,340 shares of company stock worth $2,429,061. Company insiders own 7.34% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sigma Planning Corp increased its position in shares of Aptose Biosciences by 2.9% in the 2nd quarter. Sigma Planning Corp now owns 247,855 shares of the biotechnology company’s stock valued at $1,564,000 after buying an additional 6,890 shares in the last quarter. Royal Bank of Canada increased its position in shares of Aptose Biosciences by 27.3% in the 1st quarter. Royal Bank of Canada now owns 11,618 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 2,495 shares in the last quarter. Corriente Advisors LLC increased its holdings in Aptose Biosciences by 544.1% during the 1st quarter. Corriente Advisors LLC now owns 2,918,000 shares of the biotechnology company’s stock worth $17,333,000 after purchasing an additional 2,464,960 shares in the last quarter. Advisor Group Holdings Inc. bought a new position in Aptose Biosciences during the 1st quarter worth about $471,000. Finally, Jane Street Group LLC bought a new position in Aptose Biosciences during the 1st quarter worth about $62,000. Institutional investors and hedge funds own 39.38% of the company’s stock.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.05). As a group, sell-side analysts forecast that Aptose Biosciences will post -0.65 earnings per share for the current fiscal year.
APTO has been the topic of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $10.00 price objective on shares of Aptose Biosciences in a report on Tuesday, June 23rd. BidaskClub cut shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Oppenheimer started coverage on shares of Aptose Biosciences in a research report on Sunday, June 14th. They set a “buy” rating and a $9.00 target price for the company. Maxim Group started coverage on shares of Aptose Biosciences in a research report on Friday, June 12th. They set a “buy” rating and a $16.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.79.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More: The limitations of an equal weight rating
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.